Dynamically filtered beat detection in an implantable cardiac device

Information

  • Patent Grant
  • 8548573
  • Patent Number
    8,548,573
  • Date Filed
    Monday, January 18, 2010
    14 years ago
  • Date Issued
    Tuesday, October 1, 2013
    11 years ago
Abstract
Methods and implantable devices that detect cardiac events using dynamic filtering. Illustratively, default filtering is performed except for a predefined period of time following detection of cardiac events, during which post-beat filtering is performed instead. The example post-beat filtering applies a narrower pass-band to the signal than the default filtering in order to attenuate T-waves more greatly than the default filtering during a time period after a detected event that is expected to correspond to occurrence of T-waves.
Description
FIELD

The present invention relates to the field of implantable cardiac devices, including monitoring and stimulus devices. More particularly, the present invention relates to beat detection in such devices.


SUMMARY

The present invention, in a first illustrative embodiment, includes a method of detecting cardiac events in which a first filtering approach is used as a default and, when a beat is detected, a second filtering approach is used during an interval following the detected beat. In some examples, a refractory period is defined around the detected beat, and the second filtering approach is used during an interval following the refractory period. The second filtering approach may include more aggressive and frequency specific filtering directed at eliminating certain cardiac artifacts such as T-waves, relative to the first filtering approach. In addition to methods, the present invention also includes embodiments in the form of systems and implantable devices.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates the frequency content of typical signals that an implantable cardiac device encounters during operation;



FIG. 2 illustrates the application of filtering and refractory periods to a cardiac signal for an illustrative embodiment;



FIGS. 3A-3C demonstrate three configurations for performing filtering and detection in illustrative embodiments;



FIG. 4 shows an illustrative subcutaneous implantable defibrillator;



FIG. 5 shows an illustrative transvenous implantable defibrillator; and



FIG. 6 shows frequency content and filter response for an illustrative embodiment.





DETAILED DESCRIPTION

The following detailed description should be read with reference to the drawings. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention. Any references to other patents or patent applications are intended as illustrative of useful methods or devices and are not intended to foreclose suitable alternatives.



FIG. 1 illustrates the frequency content of typical signals that an implantable cardiac device encounters during operation. The signals shown omit the potential impact of motion artifact, but cover many other potential system inputs. The height of each block generally corresponds to typical amplitude ranges. The horizontal axis represents frequency in log format.


Cardiac signal is characterized in the chart of FIG. 1 by T-waves, R-waves and P-waves; other “waves” in the cardiac signal are typically of lesser amplitude and are not represented in the drawing. The QRS complex is often referred to as the heart “beat”. Non-cardiac sources of interference can include myopotentials, which are generated by any non-cardiac muscle in the body, external line noise and/or other sources of noise. The external line noise varies in frequency depending on geographic region. In the example shown, external line noise is shown as 60 Hz line noise, which would occur in the United States. As is known in the art, other geographies may have 50 Hz line noise instead. Other sources of interference, whether intermittent or pervasive, are omitted for simplicity.


As can be seen, T-wave and R-wave signals are relatively lower in frequency than the line noise and myopotentials, and T-waves typically have a lower frequency content than the R-waves. Thus, frequency selectivity can be used to eliminate certain non-cardiac signals. It has been known to use notch filtering to attenuate line noise, and bandpass filtering can also be used. For example, U.S. Pat. No. 6,754,528 suggests the use of a Narrow Band filter with corner frequencies at approximately 10 Hz and 30 Hz, with a parallel Wide Band filter having corner frequencies at approximately 1 Hz and 50 Hz. In U.S. Pat. No. 6,754,528, the outputs of the two filters may be used for different purposes, for example, with the Narrow Band filtered signal used for event detection and the Wide Band filtered signal used for beat morphology analysis. In additional examples, filters may be modified in response to detected conditions, such as in US Patent Application Publication Number 2007-0032829, wherein a high pass filter can be bypassed in response to high beat rate to avoid attenuating low frequency components of the signal.


Several illustrative embodiments perform a different process in which cardiac signal data is filtered according to its timing relative to detected events. In other illustrative embodiments, beat detection is performed using differently filtered signals at different times relative to previous detected events. FIG. 2 provides a graphic illustration.



FIG. 2 illustrates the application of filtering and refractory periods to a cardiac signal for an illustrative embodiment. A refractory period is a time period during which additional cardiac events are not declared by the system; sensing input circuitry may be on or off during refractory, as desired. In some examples, signals are captured during the refractory period to support morphology analysis of detected events.


The captured cardiac signal trace is shown at 10 and includes repetitive signal features marked according to standard convention as P, Q, R, S and T waves. Detection of events for this signal can be performed using a detection profile, for example as set forth in commonly assigned US Patent Application Publication Number 2009-0228057, titled ACCURATE CARDIAC EVENT DETECTION IN AN IMPLANTABLE CARDIAC STIMULUS DEVICE, the disclosure of which is incorporated herein by reference. For example, the captured signal is compared to a detection threshold and when the amplitude of the captured signal exceeds the detection threshold, a detected event is declared. For simplicity of illustration, detection profiles are not shown in FIG. 2. Any other suitable methods of detection may be used instead.


Detections are indicated at the X-es shown at 12 and 14. Upon each detection 12, 14, corresponding refractory periods 16, 18 start. Each refractory period 16, 18 has a predetermined duration. As noted in the 2009-0228057 Publication, the refractory periods may vary in duration in response to detected conditions such as amplitude similarities and/or calculated event/beat rate.


Ordinarily the system uses a default filter noted as “Filter 1,” as indicated at 20, 24. Filter 1 may use frequency selective filtering such as bandpass filtering and/or notch filtering, as desired and known in the art. Upon termination of the refractory periods 16, 18, a time period is defined for use of “Filter 2”, as indicated at 22, 26. In the illustrative example, Filter 2 provides different frequency selectivity to the detection circuitry/module of the system when compared to Filter 1, which is applied during other time periods shown at 20, 24. Filter 1 may be considered the default filter for the system, while Filter 2 is applied for a period of time following refractory. As can be seen from comparison to the signal 10, the time periods during which Filter 2 is applied at 22, 26 correspond to T-waves occurring in the cardiac signal 10. The use of Filter 1 and Filter 2 may parallel other steps in the overall detection method, such as the use of constant threshold periods as shown in the 2009-0228057 Publication. In another example, a third filter, Filter 3, is applied during the refractory period or another predetermined period initially following the detection, where Filter 3 is designed to support morphology analysis of the system, as in U.S. Pat. No. 6,754,528.


In several examples, Filter 2 is designed to more greatly attenuate frequencies that correspond to T-waves. For example, Filter 2 may include additional attenuation for frequencies between 3-15 Hz. In one example, Filter 1 sets the high-pass frequency corner of its passband in the range of 1-5 Hz, while Filter 2 moves the high-pass frequency corner of its passband to a higher level in the range of 3-10 Hz. Following are some illustrative numeric examples:














Filter 1 High Pass
Filter 2 High Pass
Filters 1 and 2 Low Pass







1 Hz
 3 Hz
40 Hz


1 Hz
10 Hz
40 Hz


3 Hz
10 Hz
50 Hz


5 Hz
12 Hz
40 Hz









As noted, the Filter 2 approach can be applied for a limited period of time following refractory. In one example, the refractory period is in the range of 100-250 milliseconds, and the time period for applying Filter 2 is in the range of 100-200 milliseconds. For example, the refractory period may be about 160 milliseconds and the time period for Filter 2 may be about 140 milliseconds. In another example, the refractory period may be variable depending on cardiac conditions such as rate, and the time period for Filter 2 may adjust such that the sum of the refractory plus Filter 2 timer periods is generally constant in the range of 250-450 milliseconds. The examples may help to attenuate the T-wave during a time period where the system is susceptible to R-wave double/triple detection and T-wave overdetection.



FIGS. 3A-3C demonstrate three configurations for performing filtering and detection in illustrative embodiments. Each example references an input signal 50, 70, 90. The input signals 50, 70, 90 may be analog pre-amplifier, analog post-amplifier, and/or digital signals.



FIG. 3A shows an example in which the input signal 50 is fed to a cascade of filters, including Filter 1, at 52, which provides an input to a default detection block 54, and Filter 2, at 56, which provides an input to a Post-Beat detection block 58. FIG. 3B shows an example in which the input signal 70 is fed to Filter 1, at 72, in parallel with Filter 2, at 74, and detection block 76 selects which filter 72, 74 to use at any given time depending upon when the last beat was detected. FIG. 3C shows an example in which the input signal 90 is fed to Filter 1, at 92, and Filter 2, at 94, in parallel, and each of the filters 92, 94 is used by different detection blocks, the default detection block 96 or the post-beat detection block 98.


Reviewing FIGS. 3A-3C, it should be noted that depending upon the design of analog and/or digital filters in these systems, it can be difficult to turn on or turn off filters without introducing additional filter-related-artifacts to the signal. Thus, FIGS. 3A and 3C both show examples in which separate detection systems are applied to different filter outputs. In FIG. 3B it is assumed that filter switching can occur without creating additional noise. In addition, each example of FIGS. 3A-3C shows multiple filters and, if desired, one of the filters may be applied in the digital domain while the other is applied in the analog domain. In some examples, the system may simply switch additional filtering components in/out of the circuit during operation, without adding additional layers of detection circuits. While separate blocks are shown for the different filters, it should be understood that physically separate implementation is not necessary; separate data processing may occur within a single physical unit such as a microcontroller. The use of separate blocks is merely for illustrative purposes.



FIG. 4 shows an illustrative subcutaneous implantable defibrillator. The illustrative system is shown relative to a patient's heart 100 and includes a canister 102 coupled to a lead 104 having electrodes 106, 108, 110. The canister 102 includes an electrode 112, such that the implanted system provides multiple sensing vectors shown at A-Can (between electrodes 106 and 112), B-Can (between electrodes 110 and 112) and A-B (between electrodes 106 and 110). Additional sensing vectors may use electrode 108, which is shown as a relatively larger electrode and may take the form of a coil, as desired. Various designs can be used. Stimulus delivery in the illustrative system may use any chosen pair or combination of three or more electrodes; in one example, stimulus is provided between electrodes 108 and 112. The canister 102 is shown as having an isolated button electrode 112; in other embodiments much of the exterior of the canister, rather than an isolated portion, can be used as an electrode. A programmer 114 is also shown, and may be used as is known in the art to communicate with the implanted system to perform various diagnostic, programming, testing and other functions. A single vector may be selected for sensing, or multiple vectors may be used simultaneously.


The system of FIG. 4 is shown as a subcutaneous-only system lacking transvenous, endocardial and/or epicardial electrodes. The location is illustrated with a parasternal lead 104 extending from a lateral canister approximately located at the left axilla of the patient, such that electrode 110 is near the xiphoid of the patient with electrodes 108 and 106 more superiorly located along the sternum. Other subcutaneous-only implant locations can also be used, including anterior-posterior placements, anterior only placement, and/or lateral-posterior placement.



FIG. 5 shows an illustrative transvenous implantable defibrillator. The transvenous system is shown relative to the patient's heart 130 and includes a canister 132 coupled to a lead 134 that extends transvenously into the heart 130 through the using venous access via the subclavian vein. The lead 134 includes electrodes 136, 138 that are disposed within the heart, and the canister 132 includes a canister electrode 140. A programmer 142 is again provided for communication with the implanted system.


The implanted systems can use any suitable technology for such aspects as the lead design, electrodes, canister design, electronics, batteries, communication circuitry etc. In one illustrative example, the canister contains operational circuitry including input circuitry having passive filtering components, a vector selection switch array, one or more ECG amplifiers and analog-to-digital conversion circuitry. A microcontroller may receive signal from this input circuitry. Various battery chemistries can be used, such as lithium-magnesium battery cells. Illustrative output circuitry that can also be part of the operational circuitry may include an H-bridge-type system having multiple legs and high and low sides with high power switches that enable multi-phasic therapy delivery. Therapy may be delivered from capacitors that can be charged with a charging circuit (such as a flyback transformer circuit) taking current from the battery cells, each of which may also be part of the operational circuitry. The canister itself may be formed of titanium, stainless steel or other suitable material and may include coatings such as titanium nitride, iridium oxide, porous carbon, etc. The leads may be formed of suitable biocompatible materials such as silicone, polyurethane, polycarbonate, and/or blends thereof or other polymers, coated or uncoated. The leads may contain conductors made, for example, with stainless steel (including MP35N alloy), silver, etc., in various forms including drawn filled tube designs. The electrodes can be coated or uncoated and may also be formed of suitable materials such as MP35N and other stainless steels, platinum, gold, silver, or titanium, for example.



FIG. 6 shows frequency content and filter response for an illustrative embodiment. Although presented in a form similar to a Bode plot, the graphic in FIG. 6 is merely illustrative and is not necessarily to scale.


The chart of typical amplitudes versus frequency, as shown in FIG. 1, is condensed for illustration as shown at 200. Two filter gain profiles are shown at 202 and 204. Filter 1, shown at 202, has a gain profile that allows maximum gain across frequencies from about 4 Hz to about 50 Hz, with a notch at 60 Hz and attenuation at higher frequencies. Filter 2, shown at 204, as a gain profile that allows maximum gain across a smaller range of frequencies, attenuating the T-waves occurring below 10 Hz to a greater extent than Filter 1. As indicated, the High Pass corner frequency is moved out to about 10 Hz. While a relatively gradual slope is shown, those skilled in the art will recognize that digital filter designs in particular can provide steep gain dropoff at desired corner frequencies.


In some examples, rather than Notch filter at the line frequency, the system may use a low pass filter having a very steep profile in the range of 40 Hz or so, which will function to attenuate line frequencies in various geographies.


The following US Patents, application publications, and provisional applications are incorporated herein by reference as illustrative examples for design, operation and implantation of cardiac devices: U.S. Pat. No. 6,647,292, titled UNITARY SUBCUTANEOUS ONLY IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR AND OPTIONAL PACER; U.S. Pat. No. 6,721,597, titled SUBCUTANEOUS ONLY IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR AND OPTIONAL PACER; U.S. Pat. No. 6,754,528, titled APPARATUS AND METHOD OF ARRHYTHMIA DETECTION IN A SUBCUTANEOUS IMPLANTABLE CARDIOVERTER/DEFIBRILLATOR; U.S. Pat. No. 7,149,575, titled SUBCUTANEOUS CARDIAC STIMULATOR DEVICE HAVING AN ANTERIORLY POSITIONED ELECTRODE; U.S. Pat. No. 7,330,757, titled METHOD FOR DISCRIMINATING BETWEEN VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS; U.S. Pat. No. 7,248,921, titled METHOD AND DEVICES FOR PERFORMING CARDIAC WAVEFORM APPRAISAL; U.S. Pat. No. 7,392,085, titled MULTIPLE ELECTRODE VECTORS FOR IMPLANTABLE CARDIAC TREATMENT DEVICES; US Patent Application Publication Number 2006-0122676, titled APPARATUS AND METHOD FOR SUBCUTANEOUS ELECTRODE INSERTION, now U.S. Pat. No. 7,655,014; U.S. Pat. No. 7,376,458, titled METHOD FOR DEFINING SIGNAL TEMPLATES IN IMPLANTABLE CARDIAC DEVICES; U.S. Pat. No. 7,477,935, titled METHOD AND APPARATUS FOR BEAT ALIGNMENT AND COMPARISON; US Patent Application Publication Number 2006-0167503, titled METHOD FOR ADAPTING CHARGE INITIATION FOR AN IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR, now U.S. Pat. No. 8,160,697; US Patent Application Publication Number 2009-0228057, titled ACCURATE CARDIAC EVENT DETECTION IN AN IMPLANTABLE CARDIAC STIMULUS DEVICE; US Patent Application Publication Number 2009-0259271, titled METHODS AND DEVICES FOR ACCURATELY CLASSIFYING CARDIAC ACTIVITY, now U.S. Pat. No. 8,160,686; U.S. Pat. No. 7,623,913, titled IMPLANTABLE MEDICAL DEVICES USING HEURISTIC FILTERING IN CARDIAC EVENT DETECTION; U.S. Pat. No. 7,623,909, titled IMPLANTABLE MEDICAL DEVICES AND PROGRAMMERS ADAPTED FOR SENSING VECTOR SELECTION; US Patent Application Publication Number 2009-0036944, titled ELECTROMAGNETIC INTERFERENCE SHIELDING IN AN IMPLANTABLE MEDICAL DEVICE, now U.S. Pat. No. 7,769,457; US Patent Application Publication Number 2009-0198296, titled ADAPTIVE SHOCK DELIVERY IN AN IMPLANTABLE CARDIAC STIMULUS DEVICE, now U.S. Pat. No. 8,244,349; US Patent Application Publication Number 2009-0187227, titled DATA MANIPULATION FOLLOWING DELIVERY OF A CARDIAC STIMULUS IN AN IMPLANTABLE CARDIAC STIMULUS DEVICE; U.S. Provisional Patent Application Ser. No. 61/221,316, titled CONFIRMATION OF TREATABLE ARRHYTHMIA IN IMPLANTABLE CARDIAC STIMULUS DEVICES; U.S. Provisional Patent Application Ser. No. 61/255,249, titled METHODS AND DEVICES FOR IDENTIFYING OVERDETECTION OF CARDIAC SIGNALS; and U.S. Provisional Patent Application Ser. No. 61/255,253, titled ADAPTIVE WAVEFORM APPRAISAL IN AN IMPLANTABLE CARDIAC SYSTEM. These patents and publications are incorporated for illustrative purposes and the present invention may be used in other implantable cardiac systems as well, including monitoring systems and/or transvenous or epicardial systems.


Those skilled in the art will recognize that the present invention may be manifested in a variety of forms other than the specific embodiments described and contemplated herein. Accordingly, departures in form and detail may be made without departing from the scope and spirit of the present invention.

Claims
  • 1. A method of cardiac signal analysis in an implantable cardiac stimulus or monitoring device, the device comprising an implantable canister housing operational circuitry and having a plurality of electrodes coupled to the operational circuitry; the method comprising: capturing a signal from a chosen set of the plurality of electrodes; andperforming cardiac beat detection by comparing a detection threshold to an amplitude of the captured signal by: a) using a signal that undergoes post-beat filtering for a predefined period of time following the detected cardiac event; andb) using a signal that undergoes default filtering once the predefined period of time has expired;wherein the post-beat filtering is configured to attenuate frequencies correlated to T-waves more greatly than the default filtering;wherein the method is performed on a beat-by-beat basis, such that after detection of a cardiac beat, beat detection using the post-beat filtering is performed and, if no additional beat is detected during the predefined period of time following the detected cardiac event, beat detection using the default filtering is performed.
  • 2. The method of claim 1 wherein the default filtering includes a default high pass filter having a corner frequency in the range of 1-5 Hz and the post-beat filtering includes a post-beat high pass filter having a corner frequency in the range of 3-10 Hz, wherein the corner frequency of the default high pass filter is lower than the corner frequency of the post-beat high pass filter.
  • 3. The method of claim 1 wherein the default filtering includes a default high pass filter having a corner frequency in the range of about 3 Hz and the post-beat filtering includes a post-beat high pass filter having a corner frequency in the range of about 10 Hz.
  • 4. The method of claim 1 wherein the post-beat filtering occurs for a period of time in the range of about 250 milliseconds.
  • 5. The method of claim 1 further comprising defining a refractory period in which a new cardiac event cannot be declared following detection of a cardiac event, wherein the post-beat filtering is performed following expiration of the refractory period.
  • 6. The method of claim 5 wherein the refractory period has a variable duration, and the sum of the duration of the refractory period and the duration of the predefined period of time for performing post-beat filtering is constant.
  • 7. An implantable cardiac stimulus device (ICSD) comprising: operational circuitry including a power supply, output capacitor, and microcontroller, the microcontroller controlling operations in the ICSD; anda plurality of electrodes electrically coupled to the operational circuitry to allow sensing of cardiac events; wherein the operational circuitry is configured to perform the following method:capturing a signal using a selected set of the plurality of electrodes; andperforming cardiac beat detection by comparing a detection threshold to an amplitude of the captured signal by: a) using a signal that undergoes post-beat filtering for a predefined period of time following the detected cardiac event; andb) using a signal that undergoes default filtering once the predefined period of time has expired;wherein the post-beat filtering is configured to attenuate frequencies correlated to T-waves more greatly than the default filteringwherein the cardiac beat detection is performed on a beat-by-beat basis, such that after detection of a cardiac beat, beat detection using the post-beat filtering is performed and, if no additional beat is detected during the predefined period of time following the detected cardiac event, beat detection using the default filtering is performed.
  • 8. The ICSD of claim 7 wherein the operational circuitry is further configured such that the default filtering includes a default high pass filter having a corner frequency in the range of 1-5 Hz and the post-beat filtering includes a post-beat high pass filter having a corner frequency in the range of 3-10 Hz, wherein the corner frequency of the default high pass filter is lower than the corner frequency of the post-beat high pass filter.
  • 9. The ICSD of claim 7 wherein the operational circuitry is further configured such that the default filtering includes a default high pass filter having a corner frequency in the range of about 3 Hz and the post-beat filtering includes a post-beat high pass filter having a corner frequency in the range of about 10 Hz.
  • 10. The ICSD of claim 7 wherein the operational circuitry is further configured such that the post-beat filtering occurs for a period of time in the range of about 250 milliseconds.
  • 11. The ICSD of claim 7 wherein the operational circuitry is further configured such that the method also comprises defining a refractory period in which a new cardiac event cannot be declared following detection of a cardiac event, wherein the post-beat filtering is performed following expiration of the refractory period.
  • 12. The ICSD of claim 11 wherein the operational circuitry is further configured such that the refractory period has a variable duration, and the sum of the duration of the refractory period and the duration of the predefined period of time for performing post-beat filtering is constant.
  • 13. The ICSD of claim 7 further comprising an implantable canister housing the operational circuitry and a lead electrode assembly coupled to the implantable canister, wherein the lead electrode assembly includes at least two of the electrodes and the canister includes at least one of the electrodes.
  • 14. An implantable medical device (IMD) comprising: operational circuitry, the operational circuitry including a power supply, memory, and a microcontroller, the microcontroller controlling operations in the IMD; anda plurality of electrodes electrically coupled to the operational circuitry to allow sensing of cardiac events; wherein the operational circuitry is configured to perform the following method:capturing a signal using a selected set of the plurality of electrodes; anddetecting cardiac events by comparing a detection threshold to an amplitude of the captured signal by: a) using a signal that undergoes post-beat filtering for a predefined period of time following the detected cardiac event; andb) using a signal that undergoes default filtering once the predefined period of time has expired;wherein the post-beat filtering is configured to attenuate frequencies correlated to T-waves more greatly than the default filteringwherein the detecting cardiac events is performed on a beat-by-beat basis, such that after detection of a cardiac beat, beat detection using the post-beat filtering is performed and, if no additional beat is detected during the predefined period of time following the detected cardiac event, beat detection using the default filtering is performed.
  • 15. The IMD of claim 14 wherein the operational circuitry is further configured such that the default filtering includes a default high pass filter having a corner frequency in the range of 1-5 Hz and the post-beat filtering includes a post-beat high pass filter having a corner frequency in the range of 3-10 Hz, wherein the corner frequency of the default high pass filter is lower than the corner frequency of the post-beat high pass filter.
  • 16. The IMD of claim 14 wherein the operational circuitry is further configured such that the default filtering includes a default high pass filter having a corner frequency in the range of about 3 Hz and the post-beat filtering includes a post-beat high pass filter having a corner frequency in the range of about 10 Hz.
  • 17. The IMD of claim 14 wherein the operational circuitry is further configured such that the post-beat filtering occurs for a period of time in the range of about 250 milliseconds.
  • 18. The IMD of claim 14 wherein the operational circuitry is further configured such that the method also comprises defining a refractory period in which a new cardiac event cannot be declared following detection of a cardiac event, wherein the post-beat filtering is performed following expiration of the refractory period.
  • 19. The IMD of claim 18 wherein the operational circuitry is further configured such that the refractory period has a variable duration, and the sum of the duration of the refractory period and the duration of the predefined period of time for performing post-beat filtering is constant.
  • 20. The IMD of claim 14 further comprising an implantable canister housing the operational circuitry and a lead electrode assembly coupled to the implantable canister, wherein the lead electrode assembly includes at least two of the electrodes and the canister includes at least one of the electrodes.
US Referenced Citations (216)
Number Name Date Kind
4184493 Langer et al. Jan 1980 A
4300567 Kolenik et al. Nov 1981 A
4407288 Langer et al. Oct 1983 A
4450527 Sramek May 1984 A
4457315 Bennish Jul 1984 A
4595009 Leinders Jun 1986 A
4679144 Cox et al. Jul 1987 A
4693253 Adams Sep 1987 A
4750494 King Jun 1988 A
4779617 Whigham Oct 1988 A
4979110 Albrecht et al. Dec 1990 A
4989602 Sholder et al. Feb 1991 A
5000189 Throne et al. Mar 1991 A
5105810 Collins et al. Apr 1992 A
5184616 Weiss Feb 1993 A
5193535 Bardy et al. Mar 1993 A
5215098 Steinhaus et al. Jun 1993 A
5217021 Steinhaus et al. Jun 1993 A
5271411 Ripley et al. Dec 1993 A
5280792 Leong et al. Jan 1994 A
5299119 Kraf et al. Mar 1994 A
5313953 Yomtov et al. May 1994 A
5331966 Bennett et al. Jul 1994 A
5342402 Olson et al. Aug 1994 A
5342407 Dahl et al. Aug 1994 A
5351696 Riff et al. Oct 1994 A
5376104 Sakai et al. Dec 1994 A
5423326 Wang et al. Jun 1995 A
5447519 Peterson Sep 1995 A
5522852 White et al. Jun 1996 A
5534019 Paspa Jul 1996 A
5545186 Olson et al. Aug 1996 A
5558098 Fain Sep 1996 A
5607455 Armstrong Mar 1997 A
5658317 Haefner et al. Aug 1997 A
5709215 Perttu et al. Jan 1998 A
5817134 Greenhut et al. Oct 1998 A
5827197 Bocek et al. Oct 1998 A
5857977 Caswell et al. Jan 1999 A
5991657 Kim Nov 1999 A
6041251 Kim et al. Mar 2000 A
6047210 Kim et al. Apr 2000 A
6052617 Kim Apr 2000 A
6058328 Levine et al. May 2000 A
6095987 Shmulewitz et al. Aug 2000 A
6115628 Stadler et al. Sep 2000 A
6144879 Gray Nov 2000 A
6148230 KenKnight Nov 2000 A
6223078 Marcovecchio Apr 2001 B1
6230055 Sun et al. May 2001 B1
6236882 Lee et al. May 2001 B1
6240313 Esler May 2001 B1
6266554 Hsu et al. Jul 2001 B1
6280462 Hauser et al. Aug 2001 B1
6308095 Hsu et al. Oct 2001 B1
6334071 Lu Dec 2001 B1
6377844 Graen Apr 2002 B1
6381493 Stadler et al. Apr 2002 B1
6393316 Gillberg et al. May 2002 B1
6397100 Stadler et al. May 2002 B2
6411844 Kroll et al. Jun 2002 B1
6438410 Hsu et al. Aug 2002 B2
6449503 Hsu Sep 2002 B1
6493579 Gilkerson et al. Dec 2002 B1
6493584 Lu Dec 2002 B1
6505068 Bonnet et al. Jan 2003 B2
6516225 Florio Feb 2003 B1
6561984 Turcott May 2003 B1
6567691 Stadler May 2003 B1
6574505 Warren Jun 2003 B1
6575912 Turcott Jun 2003 B1
6587720 Hsu et al. Jul 2003 B2
6625490 McClure et al. Sep 2003 B1
6643549 Bradley et al. Nov 2003 B1
6647292 Bardy et al. Nov 2003 B1
6684100 Sweeney et al. Jan 2004 B1
6699200 Cao et al. Mar 2004 B2
6708058 Kim et al. Mar 2004 B2
6708062 Ericksen et al. Mar 2004 B2
6721597 Bardy et al. Apr 2004 B1
6728572 Hsu et al. Apr 2004 B2
6731978 Olson et al. May 2004 B2
6745068 Koyrakh et al. Jun 2004 B2
6754528 Bardy et al. Jun 2004 B2
6889079 Bocek et al. May 2005 B2
6909916 Spinelli et al. Jun 2005 B2
6950702 Sweeney Sep 2005 B2
7016730 Ternes Mar 2006 B2
7020523 Lu et al. Mar 2006 B1
7027856 Zhou et al. Apr 2006 B2
7027858 Cao et al. Apr 2006 B2
7027862 Dahl et al. Apr 2006 B2
7031764 Schwartz et al. Apr 2006 B2
7062314 Zhu et al. Jun 2006 B2
7062315 Koyrakh et al. Jun 2006 B2
7062322 Stadler et al. Jun 2006 B2
7076289 Sarkar et al. Jul 2006 B2
7085599 Kim et al. Aug 2006 B2
7117035 Wagner et al. Oct 2006 B2
7149575 Ostroff et al. Dec 2006 B2
7162301 Kim et al. Jan 2007 B2
7167747 Gunderson et al. Jan 2007 B2
7184815 Kim et al. Feb 2007 B2
7184818 Kim et al. Feb 2007 B2
7191004 Kim et al. Mar 2007 B2
7194302 Bardy et al. Mar 2007 B2
7218966 Haefner May 2007 B2
7236819 Brockway et al. Jun 2007 B2
7248921 Palreddy et al. Jul 2007 B2
7266409 Gunderson Sep 2007 B2
7283863 Gunderson Oct 2007 B2
7302294 Kamath et al. Nov 2007 B2
7330757 Ostroff et al. Feb 2008 B2
7346392 KenKnight Mar 2008 B2
7376458 Palreddy et al. May 2008 B2
7379772 Bardy et al. May 2008 B2
7386342 Falkenberg et al. Jun 2008 B1
7392085 Warren et al. Jun 2008 B2
7444182 Ostroff et al. Oct 2008 B2
7447540 Nabutovsky et al. Nov 2008 B1
7467009 Palreddy et al. Dec 2008 B2
7477935 Palreddy et al. Jan 2009 B2
7496408 Ghanem et al. Feb 2009 B2
7496409 Greenhut et al. Feb 2009 B2
7499750 Haefner et al. Mar 2009 B2
7522959 Hauser et al. Apr 2009 B2
7546159 Nabutovsky et al. Jun 2009 B1
7555335 Kamath et al. Jun 2009 B2
7559900 Gillberg Jul 2009 B2
7567835 Gunderson et al. Jul 2009 B2
7570997 Lovett et al. Aug 2009 B2
7593771 Yonce et al. Sep 2009 B2
7623909 Sanghera et al. Nov 2009 B2
7623913 Phillips Nov 2009 B2
7623916 Julian Nov 2009 B2
7655014 Ko et al. Feb 2010 B2
7682316 Anderson et al. Mar 2010 B2
7684864 Olson et al. Mar 2010 B2
7715906 Krause et al. May 2010 B2
7734345 Cinbis Jun 2010 B2
7761142 Ghanem et al. Jul 2010 B2
7774049 Ghanem et al. Aug 2010 B2
7783354 Gunderson Aug 2010 B2
7797036 Zhang et al. Sep 2010 B2
7865233 Haefner Jan 2011 B2
7894894 Stadler et al. Feb 2011 B2
7904142 Kim et al. Mar 2011 B2
7904153 Greenhut et al. Mar 2011 B2
7907993 Ghanem et al. Mar 2011 B2
7983749 Warren Jul 2011 B2
20040215239 Favet et al. Oct 2004 A1
20040215240 Lovett et al. Oct 2004 A1
20040220628 Wagner Nov 2004 A1
20040230229 Lovett et al. Nov 2004 A1
20050107838 Lovett et al. May 2005 A1
20050131464 Heinrich et al. Jun 2005 A1
20050154421 Ousdigian Jul 2005 A1
20060122676 Ko et al. Jun 2006 A1
20060167502 Haefner Jul 2006 A1
20060167503 Warren et al. Jul 2006 A1
20060167504 Warren et al. Jul 2006 A1
20060241701 Markowitz et al. Oct 2006 A1
20070032829 Ostroff Feb 2007 A1
20070049975 Cates et al. Mar 2007 A1
20070135847 Kenknight Jun 2007 A1
20070142736 Cazares et al. Jun 2007 A1
20070156190 Cinbis et al. Jul 2007 A1
20070179539 Degroot et al. Aug 2007 A1
20070179540 Stegemann et al. Aug 2007 A1
20070232944 Ghanem et al. Oct 2007 A1
20070232945 Kleckner et al. Oct 2007 A1
20070232948 Stadler et al. Oct 2007 A1
20070233198 Ghanem et al. Oct 2007 A1
20070260151 Clifford Nov 2007 A1
20070276445 Sanghera et al. Nov 2007 A1
20080015647 Palreddy et al. Jan 2008 A1
20080077030 Ostroff et al. Mar 2008 A1
20080086174 Libbus et al. Apr 2008 A1
20080091242 Kamath et al. Apr 2008 A1
20080132965 Ostroff et al. Jun 2008 A1
20080161870 Gunderson Jul 2008 A1
20080172098 Gunderson Jul 2008 A1
20080183085 Van Oort et al. Jul 2008 A1
20080188901 Sanghera et al. Aug 2008 A1
20080215110 Gunderson Sep 2008 A1
20080221632 Bardy et al. Sep 2008 A1
20080228093 Dong et al. Sep 2008 A1
20080243200 Scinicariello et al. Oct 2008 A1
20080262559 Zhang et al. Oct 2008 A1
20080275516 Ghanem et al. Nov 2008 A1
20080275517 Ghanem et al. Nov 2008 A1
20080275519 Ghanem et al. Nov 2008 A1
20080275521 Warren et al. Nov 2008 A1
20090036788 Nabutovsky et al. Feb 2009 A1
20090036944 Fonte Feb 2009 A1
20090043352 Brooke et al. Feb 2009 A1
20090054796 Sanghera et al. Feb 2009 A1
20090054938 Ostroff et al. Feb 2009 A1
20090093731 Palreddy et al. Apr 2009 A1
20090156957 Linder et al. Jun 2009 A1
20090157128 Seim et al. Jun 2009 A1
20090157132 Linder et al. Jun 2009 A1
20090157137 Gilkerson et al. Jun 2009 A1
20090187227 Palreddy et al. Jul 2009 A1
20090198296 Sanghera et al. Aug 2009 A1
20090228057 Allavatam et al. Sep 2009 A1
20090240157 Liam et al. Sep 2009 A1
20090240300 Liam et al. Sep 2009 A1
20090259271 Allavatam et al. Oct 2009 A1
20100004713 Warren et al. Jan 2010 A1
20100094369 Allavatam et al. Apr 2010 A1
20100152798 Sanghera et al. Jun 2010 A1
20100152799 Sanghera et al. Jun 2010 A1
20100331904 Allavatam et al. Dec 2010 A1
20110098585 Warren et al. Apr 2011 A1
20110098775 Allavatam et al. Apr 2011 A1
Foreign Referenced Citations (1)
Number Date Country
0554208 Aug 1993 EP
Non-Patent Literature Citations (9)
Entry
U.S. Appl. No. 61/255,253, filed Oct. 27, 2009, Allavatam, et al.
U.S. Appl. No. 61/255,249, filed Oct. 27, 2009, Warren, et al.
U.S. Appl. No. 61/221,316, filed Jun. 29, 2009, Allavatam, et al.
Gunderson et al., “An Algorithm to Predict Implantable Cardioverter-Defibrillator Lead Failure,” JACC, Nov. 2004, vol. 44, No. 9, pp. 1898-1902.
Olson et al., “Onset and Stability for Ventricular Tachyarrhythmia Detection in an Implantable Pacer-Cardioverter-Defibrillator,” IEEE, (1987) pp. 167-170.
Schuder, “The Role of an Engineering Oriented Medical Research Group in Developing Improved Methods and Devices for Achieving Ventricular Defibrillation: The University of Missouri Experience,” PACE, vol. 16, Jan. 1993, pp. 95-124.
Schwake et al., “Komplikationen nit Sonden bei 340 Patienten mit einem Implantierbaren Kardioverter/Defibrillator,” Z Kardiol (1999)vol. 88, No. 8 pp. 559-565.
Swerdlow, et al., “Advanced ICD Troubleshooting: Part I,” online article at http://www.medscape.com/viewarticle/520588—print, accessed and printed Jul. 7, 2009, indicates publication Jan. 9, 2006 (publication date not confirmed).
Throne, “A Comparison of Four New Time-Domain Techniques for Discriminating Monomorphic Ventricular Tachycardia from Sinus Rhythm Using Ventricular Waveform Morphology,” IEEE Transactions on Biomedical Engineering, vol. 38, No. 6, Jun. 1991, pp. 561-570.
Related Publications (1)
Number Date Country
20110178564 A1 Jul 2011 US